GXO Logistics has been appointed by NHS England to manage the supply and distribution of home testing kits for the national bowel cancer screening programme.
Under the agreement, GXO will act as managed service provider for the Faecal Immunochemical Test (FIT) programme, overseeing the distribution of test kits to eligible participants across England. The company will work with diagnostic test providers Mast Group and RDi.
The contract marks a further expansion of GXO’s healthcare logistics operations, following its appointment by NHS Supply Chain in 2025.
Gavin Williams, managing director, GXO UK & Ireland, said: “GXO’s solutions are purpose-built for the complex and highly regulated needs of healthcare supply chains, and we are proud to be selected by NHS England to deliver this important national programme.”
“This new partnership underscores GXO’s continued investment and rapid growth in the healthcare sector and how our capabilities are driving productivity and resilience across a vital part of the UK economy and the NHS.”
The screening programme supports early detection of bowel cancer by enabling patients to carry out tests at home, reducing pressure on hospital services and improving accessibility.
Partners RDi and Mast will provide diagnostic and testing capabilities, supporting laboratory workflows and patient participation in the screening programme.
David Cahill, CEO of RDi, said: “Having been involved with the Bowel Cancer Screening Programme since its start in 2008, RDi is proud to continue to support the work of the programme in driving up participation rates and addressing inequalities.”
IntraLogisteX 2026 takes place on 17-18 March 2027 at the NEC Birmingham. For exhibitor information and visitor registration, visit the official event website at www.intralogistex.co.uk
